Share Twitter LinkedIn Facebook Email Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast cancer.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read